These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 2328949)
1. [Terminal complement complex (TTC) levels in plasma and urine from glomerular diseases: enzyme-linked immunosorbent assay (ELISA) using monoclonal antibody against neoantigens of TCC]. Kusunoki Y Hokkaido Igaku Zasshi; 1990 Jan; 65(1):74-85. PubMed ID: 2328949 [TBL] [Abstract][Full Text] [Related]
2. Using polymerized C9 to produce a monoclonal antibody against a neoantigen of the human terminal complement complex. Kusunoki Y; Takekoshi Y; Nagasawa S J Pharmacobiodyn; 1990 Jul; 13(7):454-60. PubMed ID: 2290128 [TBL] [Abstract][Full Text] [Related]
4. Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases. Horigome I; Seino J; Sudo K; Kinoshita Y; Saito T; Yoshinaga K Clin Exp Immunol; 1987 Nov; 70(2):417-24. PubMed ID: 3427827 [TBL] [Abstract][Full Text] [Related]
5. [Terminal complement complex (TCC) levels in urine in patients with renal diseases]. Yasuda K Hokkaido Igaku Zasshi; 2001 Mar; 76(2):71-84. PubMed ID: 11344904 [TBL] [Abstract][Full Text] [Related]
6. Levels of SC5b--9 complement complex in plasma and synovial fluid of patients with rheumatic disease. Rus V; Malide D; Boloşiu HD; Parasca I; Duţu AL Med Interne; 1990; 28(4):305-10. PubMed ID: 2100875 [TBL] [Abstract][Full Text] [Related]
7. Blood dendritic cells carry terminal complement complexes on their cell surface as detected by newly developed neoepitope-specific monoclonal antibodies. Würzner R; Xu H; Franzke A; Schulze M; Peters JH; Götze O Immunology; 1991 Sep; 74(1):132-8. PubMed ID: 1718850 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Mollnes TE; Lea T; Harboe M; Tschopp J Scand J Immunol; 1985 Aug; 22(2):183-95. PubMed ID: 4035298 [TBL] [Abstract][Full Text] [Related]
10. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. Falk RJ; Dalmasso AP; Kim Y; Tsai CH; Scheinman JI; Gewurz H; Michael AF J Clin Invest; 1983 Aug; 72(2):560-73. PubMed ID: 6348093 [TBL] [Abstract][Full Text] [Related]
11. Terminal complement complexes in childhood type I membranoproliferative glomerulonephritis. Kobayashi Y; Hasegawa O; Honda M J Nephrol; 2006; 19(6):746-50. PubMed ID: 17173247 [TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of the terminal complement complex in children with type I membranoproliferative glomerulonephritis]. Kobayashi Y; Hasegawa O; Honda M Nihon Jinzo Gakkai Shi; 2004 Jul; 46(5):419-25. PubMed ID: 15446597 [TBL] [Abstract][Full Text] [Related]
13. In vivo clearance studies of the terminal fluid-phase complement complex in rabbits. Hugo F; Berstecher C; Krämer S; Fassbender W; Bhakdi S Clin Exp Immunol; 1989 Jul; 77(1):112-6. PubMed ID: 2766574 [TBL] [Abstract][Full Text] [Related]
14. Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries. Niculescu F; Hugo F; Rus HG; Vlaicu R; Bhakdi S Clin Exp Immunol; 1987 Aug; 69(2):477-83. PubMed ID: 3652536 [TBL] [Abstract][Full Text] [Related]
15. Several epitopes on native human complement C9 are involved in interaction with the C5b-8 complex and other C9 molecules. Kontermann R; Deppisch R; Rauterberg EW Eur J Immunol; 1990 Mar; 20(3):623-8. PubMed ID: 1690659 [TBL] [Abstract][Full Text] [Related]
16. [ELISA for detection of SC5b-9 levels in plasma and its clinical significance in SLE disease]. Kan D Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Aug; 15(4):302-5. PubMed ID: 8168211 [TBL] [Abstract][Full Text] [Related]
17. Demonstration of apoptosis-associated cleavage products of DNA, complement activation products SC5b-9 and C3d/dg, and immune complexes CIC-C3d, CIC-IgA, and CIC-IgG in the urine of patients with membranous glomerulonephritis. Kotnik V; Premzl A; Skoberne M; Malovrh T; Kveder R; Kaplan-Pavlovcic S; Kotnik A; Stiblar-Martincic D Croat Med J; 2003 Dec; 44(6):707-11. PubMed ID: 14652883 [TBL] [Abstract][Full Text] [Related]
18. Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Jansen JH; Høgåsen K; Mollnes TE Am J Pathol; 1993 Nov; 143(5):1356-65. PubMed ID: 8238252 [TBL] [Abstract][Full Text] [Related]
19. Detection of the terminal fluid-phase complement complex, SC5b-9, in the plasma of patients with insulin-dependent (type I) diabetes mellitus. Relation to increased urinary albumin excretion and plasma von Willebrand factor. Triolo G; Giardina E; Casiglia D; Scarantino G; Bompiani GD Clin Exp Immunol; 1991 Apr; 84(1):53-8. PubMed ID: 2015712 [TBL] [Abstract][Full Text] [Related]
20. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Mollnes TE; Lea T; Frøland SS; Harboe M Scand J Immunol; 1985 Aug; 22(2):197-202. PubMed ID: 2412280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]